文献速递肝病

III度肥胖是失代偿期肝硬化患者发生慢加急性肝衰竭的危险因素

Class III obesity is a risk factor for the development of acute-on-chronic liver failure in patients with decompensated cirrhosis.
PubMed 文献 · J Hepatol · 2018-04-28

研究利用UNOS数据库2005-2016年数据及NIS数据库2009-2013年数据,分析失代偿期肝硬化患者肥胖与慢加急性肝衰竭(ACLF)的关联。多变量模型显示III度肥胖是肝移植时ACLF的独立危险因素(HR 1.24;95%CI 1.09-1.41;p<0.001),NIS数据库证实该关联(OR 1.30;95%CI 1.25-1.35;p<0.001)。肥胖患者ACLF中肾衰竭患病率更高。

要点

  • III度肥胖是失代偿期肝硬化患者发生ACLF的独立危险因素(HR 1.24;95%CI 1.09-1.41;p<0.001)。
  • NIS数据库证实III度肥胖与ACLF发生相关(OR 1.30;95%CI 1.25-1.35;p<0.001)。
  • I-II度和III度肥胖患者ACLF中肾衰竭患病率均更高。

核心结论

  • III度肥胖是新发现的失代偿期肝硬化患者发生ACLF的危险因素。
  • 肥胖患者ACLF中肾衰竭患病率特别高。
  • 这些发现对风险分层和预防ACLF发生有重要意义。

研究设计与样本

  • 分析UNOS数据库2005-2016年等待名单登记患者,按BMI分为非肥胖(<30)、I-II度肥胖(30-39.9)和III度肥胖(≥40)。
  • ACLF依据CANONIC研究定义判定,采用Cox比例风险回归评估肥胖与肝移植时ACLF发生的关联。
  • 利用NIS数据库2009-2013年数据验证,采用经验证的诊断编码算法识别肥胖、肝功能失代偿和ACLF,逻辑回归评估肥胖与ACLF发生的关联。

主要发现

  • 两个数据库共387,884例失代偿期肝硬化患者记录中,116,704例(30.1%)被识别为ACLF。
  • UNOS数据库多变量模型显示III度肥胖是肝移植时ACLF的独立危险因素(HR 1.24;95%CI 1.09-1.41;p<0.001)。
  • NIS数据库证实该关联(OR 1.30;95%CI 1.25-1.35;p<0.001)。
  • 两个登记库分析均显示I-II度和III度肥胖患者肾衰竭患病率更高。

临床怎么用

  • 作者指出这些发现对风险分层和预防ACLF发生有重要意义。
  • 作者强调肝硬化体重管理的重要性,以降低ACLF风险。
  • 作者建议III度肥胖患者应密切监测肾衰竭的发生。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Acute-on-chronic liver failure (ACLF) is a syndrome of systemic inflammation and organ failures. Obesity, also characterized by chronic inflammation, is a risk factor among patients with cirrhosis for decompensation, infection, and mortality. Our aim was to test the hypothesis that obesity predisposes patients with decompensated cirrhosis to the development of ACLF. METHODS: We examined the United Network for Organ Sharing (UNOS) database, from 2005-2016, characterizing patients at wait-listing as non-obese (body mass index [BMI] <30), obese class I-II (BMI 30-39.9) and obese class III (BMI ≥40). ACLF was determined based on the CANONIC study definition. We used Cox proportional hazards regression to assess the association between obesity and ACLF development at liver transplantation (LT). We confirmed our findings using the Nationwide Inpatient Sample (NIS), years 2009-2013, using validated diagnostic coding algorithms to identify obesity, hepatic decompensation and ACLF. Logistic regression evaluated the association between obesity and ACLF occurrence. RESULTS: Among 387,884 patient records of decompensated cirrhosis, 116,704 (30.1%) were identified as having ACLF in both databases. Multivariable modeling from the UNOS database revealed class III obesity to be an independent risk factor for ACLF at LT (hazard ratio 1.24; 95% CI 1.09-1.41; p <0.001). This finding was confirmed using the NIS (odds ratio 1.30; 95% CI 1.25-1.35; p <0.001). Regarding specific organ failures, analysis of both registries demonstrated patients with class I-II and class III obesity had a greater prevalence of renal failure. CONCLUSION: Class III obesity is a newly identified risk factor for ACLF development in patients with decompensated cirrhosis. Obese patients have a particularly high prevalence of renal failure as a component of ACLF. These findings have important implications regarding stratifying risk and preventing the occurrence of ACLF. LAY SUMMARY: In this study, we identify that among patients with decompensated cirrhosis, class III obesity (severe/morbid obesity) is a modifiable risk factor for the development of acute-on-chronic liver failure (ACLF). We further demonstrate that regarding the specific organ failures associated with ACLF, renal failure is significantly more prevalent in obese patients, particularly those with class III obesity. These findings underscore the importance of weight management in cirrhosis, to reduce the risk of ACLF. Patients with class III obesity should be monitored closely for the development of renal failure.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Sundaram V, Jalan R, Ahn JC, et al. Class III obesity is a risk factor for the development of acute-on-chronic liver failure in patients with decompensated cirrhosis. J Hepatol. 2018. PMID: 29709681. doi:10.1016/j.jhep.2018.04.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。